Targeted Oncology Staff

"These findings support carboplatin-based IC-CCRT as a promising alternative treatment option for LA-NPC," Jian Guan, MD.

During a live event, Prerna Mewawalla, MD, and participants discussed selecting therapy for patients with early relapsed/refractory multiple myeloma who are not candidates for CAR T-cell therapy.

During a live event, Brittany Siontis, MD, discussed treatment strategies for a patient with a progressive abdominal desmoid tumor.

During a live event, Bruna Pellini, MD, and participants discussed frontline treatment selection for patients with ROS1-positive advanced non–small cell lung cancer, including how evolving efficacy and tolerability data are shifting practice toward newer-generation TKIs.

The adjuvant approval of the belzutifan combination is supported by the LITESPARK-022 trial.

During a live event, Sikander Ailawadhi, MD, and participants discussed sequencing and bridging therapy selection for patients with early relapsed multiple myeloma who are candidates for CAR T-cell therapy.

The phase 3 WU-KONG28 trial found that sunvozertinib decreased disease progression risk by 35% and nearly doubled response rates vs platinum-based chemotherapy in treatment-naive patients with NSCLC harboring EGFR exon 20 insertions.

Experts debate first-line poor-risk metastatic ccRCC: ICI‑TKI for rapid control vs dual ICI for durable benefit, guided by updated NCCN 2026.

Updated data from ASCO 2026 highlight advances in TNBC and HR+ breast cancer, including novel agents, biomarker strategies, and GLP-1 RA findings.

The combo did not, however, meet the coprimary end point of absolute change in total symptom score.

During a live event, Syed Abbas Ali, MBBS, and participants discussed current referral practices for second-line CAR T-cell therapy in multiple myeloma.

Switching early to camizestrant with a CDK4/6 inhibitor after ESR1 mutation detection extends progression-free outcomes in ER-positive breast cancer, despite FDA debate.

Phase 3 data show giredestrant plus palbociclib misses significant PFS gain vs letrozole, with similar safety, guiding future trials.

FDA greenlights eight May 2026 oncology approvals, debuting first PROTAC, expanding breast ADCs, and advancing biomarker-driven bladder cancer and rare blood cancers.

During a live event, Amit Mahipal, MD, and participants discussed how to recognize and manage immune-related adverse events arising from combination regimens for unresectable HCC.

These 5 noteworthy abstracts provide a deeper dive into the 2026 ASCO gastrointestinal cancers data.

5 noteworthy abstracts from a deeper dive into the ASCO genitourinary cancers data.

During a live event, Christopher Lieu, MD, and participants discussed selecting third-line therapy for KRAS wild-type metastatic colorectal cancer.

“Further investigation of intravesical rBCG in combination with next-generation systemic regimens in randomized trials is warranted,” said Richard Cathomas, MD.

Oncologists weigh second-line options after ICI failure in metastatic ccRCC, spotlighting lenvatinib/everolimus, new agents, and ICI rechallenge.

During a live event, Firas El Chaer, MD, highlighted pivotal data informing decision making in frontline polycythemia vera.

During a live event, Amit Mahipal, MD, and participants discussed first-line treatment selection for unresectable or metastatic hepatocellular carcinoma.

“The use of GLP-1 drugs [vs] DPP-4 inhibitors…was associated with a meaningful reduction in cancer progression,” Mark David Orland, MD.

The study is the first randomized, prospective head-to-head comparison of the cognitive effects of two androgen receptor pathway inhibitors.

The ASCO 2026 lung cancer data include results for amivantamab, lazertinib, pumitamig, silevertinib, and sacituzumab tirumotecan.

During a live event, Thomas Hutson, DO, PharmD, PhD, and participants discussed current best practice with adjuvant IO post-nephrectomy.

During a live event, Ronan J. Kelly, MD, MBA, and participants discussed how they use PD-1 inhibitors in patients with upper gastrointestinal cancers.

During a live event, Binod Dhakal, MD, discussed the evidence for targeting XPO1 and GPRC5D before BCMA CAR T-cell therapy in multiple myeloma.

Dr Stein reviews PEACE-3 data supporting radium-223 plus enzalutamide in mCRPC and the role of bone-protecting agents in this setting.

During a live event, Paolo Strati, MD and participants explore when to use CAR T in relapsed LBCL, how bispecific antibodies fit, and practical scan, access, and frontline CD19 strategy shifts.